GenMark Diagnostics, Inc. (GNMK): Price and Financial Metrics

GenMark Diagnostics, Inc. (GNMK)

Today's Latest Price: $12.95 USD

0.53 (4.27%)

Updated Nov 27 1:00pm

Add GNMK to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

GNMK Stock Summary

  • With a year-over-year growth in debt of 45.53%, GenMark Diagnostics Inc's debt growth rate surpasses 80.5% of about US stocks.
  • As for revenue growth, note that GNMK's revenue has grown 85.37% over the past 12 months; that beats the revenue growth of 93.8% of US companies in our set.
  • The volatility of GenMark Diagnostics Inc's share price is greater than that of 86.57% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to GNMK, based on their financial statements, market capitalization, and price volatility, are FEYE, HCAT, LPSN, TRXC, and CLXT.
  • Visit GNMK's SEC page to see the company's official filings. To visit the company's web site, go to

GNMK Stock Price Chart Interactive Chart >

Price chart for GNMK

GNMK Price/Volume Stats

Current price $12.95 52-week high $20.88
Prev. close $12.42 52-week low $3.36
Day low $12.41 Volume 468,400
Day high $13.25 Avg. volume 1,865,618
50-day MA $13.03 Dividend yield N/A
200-day MA $11.42 Market Cap 928.79M

GenMark Diagnostics, Inc. (GNMK) Company Bio

GenMark Diagnostics, Inc. develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company is based in Carlsbad, California.

GNMK Latest News Stream

Event/Time News Detail
Loading, please wait...

GNMK Latest Social Stream

Loading social stream, please wait...

View Full GNMK Social Stream

Latest GNMK News From Around the Web

Below are the latest news stories about GenMark Diagnostics Inc that investors may wish to consider to help them evaluate GNMK as an investment opportunity.

Tracon FDA Clearance, And Other News: The Good, Bad And Ugly Of Biopharma

TRACON Pharmaceuticals gets FDA clearance for ENVASARC pivotal trial TRACON Pharmaceuticals (TCON) announced that the FDA has given its nod for a pivotal trial. The company had submitted the protocol as a part of its Investigational New Drug application with the FDA on July 15, 2020. The application had eluded...

Avisol Capital Partners on Seeking Alpha | August 19, 2020

GenMark: Near-Term Capital Gain Prospects From COVID-19 Testing Race

Investment Thesis GenMark Diagnostics (GNMK) is an active investment alternative in competition with dozens of other medical diagnostic and research enterprises. Success from an investment point of view relates more to increased stock price than lives saved. That measure here rests importantly on already-developed and proven proprietary capabilities. The comparative...

Peter F. Way, CFA on Seeking Alpha | August 6, 2020

GenMark Diagnostics to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences. GenMark’s management team is scheduled to present at the Canaccord 40th Annual Growth Conference on Wednesday, August 12th, 2020 at 3:00pm ET. Interested parties can access the live and archived webcast at’s management team will also be participating in one-on-one meetings at the 5th Annual Needham Med Tech and Diagnostics 1x1 Conference on Monday, August 17, 2020.  Due to the format of this event no webcast will be available.About GenMark Diagnostics GenMark Diagnostics (NASDAQ: GNMK) is a leading ...

Yahoo | July 29, 2020

Why A Covid-19 Vaccine Won't Halt Feverish Demand For Coronavirus Tests

You'd think that, as biopharma companies close in on an effective vaccine to do battle against Covid-19, the days of widespread coronavirus tests are numbered. Not so fast, analysts say.

Yahoo | July 24, 2020

Is GenMark Diagnostics' (NASDAQ:GNMK) Share Price Gain Of 186% Well Earned?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right stock, you can make a...

Yahoo | July 22, 2020

Read More 'GNMK' Stories Here

GNMK Price Returns

1-mo 3.60%
3-mo -1.07%
6-mo 30.15%
1-year 132.08%
3-year 194.32%
5-year 62.48%
YTD 169.23%
2019 -1.03%
2018 16.55%
2017 -65.93%
2016 57.73%
2015 -42.98%

Continue Researching GNMK

Want to see what other sources are saying about GenMark Diagnostics Inc's financials and stock price? Try the links below:

GenMark Diagnostics Inc (GNMK) Stock Price | Nasdaq
GenMark Diagnostics Inc (GNMK) Stock Quote, History and News - Yahoo Finance
GenMark Diagnostics Inc (GNMK) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8467 seconds.